| Literature DB >> 33869874 |
Ahmed A Emam1, Salwa M Abo-Elkhair2, Mohamed Sobh1,3, Ahmed M A El-Sokkary4.
Abstract
Micro-RNAs (MiRNAs) are a class of small non-coding RNAs that regulate cellular gene expression. MiR-155 overexpression has been implicated in many types of cancer. Besides, miR-155 appears to help tumor invasion and migration and works as a moderator of epithelial-to-mesenchymal transition (EMT). Exopolysaccharides (EPSs) are a large group of natural heterogeneous polymers of sugars with a biologically antitumor effect. Herein, we test a hypothesis that EPS might promote its anti-tumorigenic effect via regulating miR-155 expression and its target pathways. Expression of miR-155 and a panel of targeted genes were investigated by real-time PCR. In our study, we have succeeded in the extraction, purification of exopolysaccharide with great cytotoxicity to different cancer cell lines, HepG II, Caco-2, and MCF-7. We reported that EPSs have a suppression effect on the oncogenic miR-155. In conclusion, this work clarifies a new possible mechanism for the anti-tumorigenic effect of EPSs in cancer cells and provides insights into the biological pathways through which EPSs act. Moreover, it paves the way for new prospective cancer therapeutics as anti-miRNA.Entities:
Keywords: Breast cancer; Cancer cell lines; Colon cancer; Exopolysaccharides; HCC; miR-155
Year: 2021 PMID: 33869874 PMCID: PMC8045046 DOI: 10.1016/j.heliyon.2021.e06698
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Primer sequences for different studied genes.
| Gene | Primer Sequences | PCR Product Size |
|---|---|---|
| miRNA155 | Forward: TTAATGCTAATCGTGATAGGGGT | 55 bp |
| Reverse: ATATGTAGGAGTCAGTTGGAGGC | ||
| BRCA1 | Forward: ACAGCTGTGTGGTGCTTCTGTG | 107 bp |
| Reverse: CATTGTCCTCTGTCCAGGCATC | ||
| SOCS1 | Forward: CACTTCCGCACATTCCGTTC | 202 bp |
| Reverse: AGGCCATCTTCACGCTAAGG | ||
| MLH1 | Forward: TGCTGGCAATCAAGGGACCCAGAT | 214 bp |
| Reverse: CACGGTTGAGGCATTGGGTAGTGT | ||
| TP53 | Forward: CATAGTGTGGTGGTGCCCTATGAG | 172 bp |
| Reverse: CAAAGCTGTTCCGTCCCAGTAGA | ||
| AIFM1 | Forward: CAGAAAAAGGCCGCGTTATCT | 160 bp |
| Reverse: ATACAATCAGTACCCTGGCCCC | ||
| Rb1 | Forward: CCTCTCGTCAGGCTTGAGTT | 180 bp |
| Reverse: ACAGATTCCCCACAGTTCCT | ||
| BCL2 | Forward: CTGCACCTGACGCCCTTCACC | 119 bp |
| Reverse: CACATGACCCCACCGAACTCAAAGA | ||
| BAX | Forward: CGGGTTGTCGCCCTTTTCTA | 82 bp |
| Reverse: TGGTTCTGATCAGTTCCGGC | ||
| Caspase-9 (CASP 9) | Forward: TTCCCAGGTTTTGTTTCCTG | 143 bp |
| Reverse: CCTTTCACCGAAACAGCATT | ||
| m-TOR | Forward: GCCCAGGCCGCATTGTCTCTAT | 84 bp |
| Reverse: GCAGTAAATGCAGGTAGTCATCCAGGTT | ||
| LC3A | Forward: GCCTTCTTCCTGCTGGTGAAC | 91 bp |
| Reverse: AGCCGTCCTCGTCTTTCTCC | ||
| c-myc | Forward: AGGGAGATCCGGAGCGAATA | 156 bp |
| Reverse: GTCCTTGCTCGGGTGTTGTA | ||
| KI-67 | Forward: GTGGTTCGACAAGTGGCCTT | 224 bp |
| Reverse: ACCCCTTCCAAACAAGCAGG | ||
| K-Ras | Forward: GCCTGCTGAAAATGACTGAATATA | 81 bp |
| Reverse: TTAGCTGTATCGTCAAGGCACTC | ||
| β-Catenin (CTNNB1) | Forward: CCAGGTGGTGGTTAATAAGG | 88 bp |
| Reverse: CTGAGGAGAACGCATGATAG | ||
| BMI-1 | Forward: TCCTTAACAGTCTCAGGTATCAACC | 150 bp |
| Reverse: CACAGTTTCCTCACATTTCCA | ||
| GAPDH | Forward: TGCACCACCAACTGCTTAGC | 87 bp |
| Reverse: GGCATGGACTGTGGTCATGAG | ||
Figure 1Anti-proliferation effect of EPS on different cancer cell lines: HepG II, MCF-7, and Caco-2. "a" means relative significance to 0 μg/ml, "b" means relative significance to 200 μg/ml, "c" relative significance to 400 μg/ml, "d" relative significance to 600 μg/ml and "e" means relative significance to 800 μg/ml and "f" " relative significance to 1000 μg/ml (P < 0.05).
Figure 2Effect of EPSs on the cell cycle progression of different cells. (I) Representative Histogram showing cell cycle distribution phases in the cells treated with EPS. (a) Cells without EPS (Control), (b) Cells treated with EPS. (II) Columns show cell cycle phases percentage in the cells treated with EPS. ∗P < 0.05, ∗∗P < 0.001.
Cell Cycle Phases distribution on HepG II, MCF-7 & Caco-2 cells upon treatment with The IC50 concentration of EPS.
| HepG II | MCF-7 | Caco-2 | ||||
|---|---|---|---|---|---|---|
| Control | Treated | Control | Treated | Control | Treated | |
| G0/1 Phase | 49.5 % | 64.6 % | 64.0 % | 74.9 % | 63.7 % | 83.0 % |
| S Phase | 30.0% | 22.7 % | 17.7 % | 2.6 % | 16.9 % | 0.8 % |
| G2/M Phase | 10.5 % | 4.2 % | 0.9 % | 10.3 % | 0.5 % | 0.8 % |
Figure 3Flow cytometry analysis with Annexin V-FITC/PI. (a) Representative Histogram showing cells treated with medium used as control (I) and cells treated with EPS (II). (b) Columns show apoptosis and necrosis percentage in the cells treated with EPS.∗P < 001, ∗∗P < 0.001. Note: Upper right represent Necrosis while lower right represents Apoptosis.
The Total apoptotic and necrotic death rates on HepG II, MCF-7 & Caco-2 cells upon treatment with The IC50 concentration of EPS.
| HepG II | MCF-7 | Caco-2 | ||||
|---|---|---|---|---|---|---|
| Control | Treated | Control | Treated | Control | Treated | |
| Total Apoptotic Rate | 8.5 % | 53.4% | 5.5 % | 62.0 % | 8.2 % | 54.3 % |
| Necrotic Rate | 8.2 % | 2.6 % | 13.3 % | 4.9 % | 10.1% | 2.2 % |
Figure 4Effect of EPSs on the expression level of: (a) miRNA 155, (b) Apoptotic & Anti-apoptotic genes, (c) Autophagic genes, (d) Proliferative genes, (e) Self-Renewal genes &(f) Other genes ∗P < 0.01, ∗∗P < 0.001.